BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Skike CE, Galvan V. A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review. Gerontology 2018;64:205-11. [PMID: 29320772 DOI: 10.1159/000485381] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Riordan R, Rong W, Yu Z, Ross G, Valerio J, Dimas-muñoz J, Heredia V, Magnusson K, Galvan V, Perez V. Effect of Nrf2 Loss on Senescence and Cognition of Tau-Based P301S Mice.. [DOI: 10.1101/2022.10.31.514571] [Reference Citation Analysis]
2 Zhao Y, Wang Y, Yang D, Suh K, Zhang M. A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data. Front Pharmacol 2022;13:906429. [DOI: 10.3389/fphar.2022.906429] [Reference Citation Analysis]
3 Khonsari F, Heydari M, Sharifzadeh M, Valizadeh H, Dinarvand R, Atyabi F. Transferrin decorated-nanostructured lipid carriers (NLCs) are a promising delivery system for rapamycin in Alzheimer's disease: An in vivo study. Biomaterials Advances 2022;137:212827. [DOI: 10.1016/j.bioadv.2022.212827] [Reference Citation Analysis]
4 Di Domenico F, Lanzillotta C. The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders. Disorders of Protein Synthesis 2022. [DOI: 10.1016/bs.apcsb.2022.05.008] [Reference Citation Analysis]
5 Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules 2021;26:7213. [PMID: 34885795 DOI: 10.3390/molecules26237213] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
6 Eltanahy AM, Koluib YA, Gonzales A. Pericytes: Intrinsic Transportation Engineers of the CNS Microcirculation. Front Physiol 2021;12:719701. [PMID: 34497540 DOI: 10.3389/fphys.2021.719701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Querfurth H, Lee HK. Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol Neurodegener 2021;16:44. [PMID: 34215308 DOI: 10.1186/s13024-021-00428-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 29.0] [Reference Citation Analysis]
8 Turner DA. Contrasting Metabolic Insufficiency in Aging and Dementia. Aging Dis 2021;12:1081-96. [PMID: 34221551 DOI: 10.14336/AD.2021.0104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
9 Tu YF, Jiang ST, Chiang CW, Chen LC, Huang CC. Endothelial-specific insulin receptor substrate-1 overexpression worsens neonatal hypoxic-ischemic brain injury via mTOR-mediated tight junction disassembly. Cell Death Discov 2021;7:150. [PMID: 34226528 DOI: 10.1038/s41420-021-00548-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Perluigi M, Di Domenico F, Barone E, Butterfield DA. mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med 2021;169:382-96. [PMID: 33933601 DOI: 10.1016/j.freeradbiomed.2021.04.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
11 Van Skike CE, Hussong SA, Hernandez SF, Banh AQ, DeRosa N, Galvan V. mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease. J Neurosci 2021;41:4305-20. [PMID: 33888602 DOI: 10.1523/JNEUROSCI.2144-20.2021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
12 Pan XJ, Misrani A, Tabassum S, Yang L. Mitophagy pathways and Alzheimer's disease: From pathogenesis to treatment. Mitochondrion 2021;59:37-47. [PMID: 33872797 DOI: 10.1016/j.mito.2021.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Di Costanzo A, Paris D, Melck D, Angiolillo A, Corso G, Maniscalco M, Motta A. Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features. Sci Rep 2020;10:15612. [PMID: 32973179 DOI: 10.1038/s41598-020-71832-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
14 Su IJ, Chang HY, Wang HC, Tsai KJ. A Curcumin Analog Exhibits Multiple Biologic Effects on the Pathogenesis of Alzheimer's Disease and Improves Behavior, Inflammation, and β-Amyloid Accumulation in a Mouse Model. Int J Mol Sci 2020;21:E5459. [PMID: 32751716 DOI: 10.3390/ijms21155459] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
15 Van Skike CE, Galvan V. Cerebrovascular dysfunction links aging to neurological disease. Aging (Albany NY) 2020;12:13847-8. [PMID: 32756010 DOI: 10.18632/aging.103854] [Reference Citation Analysis]
16 Uddin MS, Rahman MA, Kabir MT, Behl T, Mathew B, Perveen A, Barreto GE, Bin-Jumah MN, Abdel-Daim MM, Ashraf GM. Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease. IUBMB Life 2020;72:1843-55. [PMID: 32472959 DOI: 10.1002/iub.2324] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
17 Kaeberlein M, Galvan V. Rapamycin and Alzheimer's disease: Time for a clinical trial? Sci Transl Med 2019;11:eaar4289. [PMID: 30674654 DOI: 10.1126/scitranslmed.aar4289] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 40.0] [Reference Citation Analysis]
18 Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of Vascular Aging. Circ Res 2018;123:849-67. [PMID: 30355080 DOI: 10.1161/CIRCRESAHA.118.311378] [Cited by in Crossref: 273] [Cited by in F6Publishing: 296] [Article Influence: 91.0] [Reference Citation Analysis]
19 Kaeberlein M, Kaskie B. Time for a New Strategy in the War on Alzheimer’s Disease. Public Policy & Aging Report 2019;29:119-22. [DOI: 10.1093/ppar/prz020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Osorio C, Kanukuntla T, Diaz E, Jafri N, Cummings M, Sfera A. The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling. Front Aging Neurosci 2019;11:143. [PMID: 31297054 DOI: 10.3389/fnagi.2019.00143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
21 Van Skike CE, Galvan V. mTOR in cerebrovascular disease. Aging (Albany NY) 2019;11:1331-2. [PMID: 30867339 DOI: 10.18632/aging.101869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Fulop GA, Tarantini S, Yabluchanskiy A, Molnar A, Prodan CI, Kiss T, Csipo T, Lipecz A, Balasubramanian P, Farkas E, Toth P, Sorond F, Csiszar A, Ungvari Z. Role of age-related alterations of the cerebral venous circulation in the pathogenesis of vascular cognitive impairment. Am J Physiol Heart Circ Physiol 2019;316:H1124-40. [PMID: 30848677 DOI: 10.1152/ajpheart.00776.2018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
23 Mueed Z, Tandon P, Maurya SK, Deval R, Kamal MA, Poddar NK. Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. Front Neurosci 2018;12:1017. [PMID: 30686983 DOI: 10.3389/fnins.2018.01017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
24 Hillson O, Gonzalez S, Rallis C. Prospects of Pharmacological Interventions to Organismal Aging. Biomolecular Concepts 2018;9:200-15. [DOI: 10.1515/bmc-2018-0018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]